© Drug Hunter Inc. 2018-2023
Home > daridorexant
dual orexin receptor GPCR antagonist
Ph. III efficacy for insomnia, oral 25-50 mg
from optimization of prior clinical candidate
ChemMedChem., Oct. 28, 2020
Idorsia Pharmaceuticals, Allschwil, CH
Idorsia clinical dual orexin receptor GPCR antagonist
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year